Oxymetholone: II. Evaluation in the Tg.AC Transgenic Mouse Model for Detection of Carcinogens

Toxicologic Pathology

Volumn 27, Issue 5, 1999, Pages 507-512

  Holden, Henry E ^a   Stoll, Raymond E ^a   Blanchard, Kerry T ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

carcinogenicity; Oxymetholone; papillomas; Tg.AC; transgenic mouse

Indexed keywords

ACETONE; CARCINOGEN; DIMETHYL SULFOXIDE; OXYMETHOLONE; PHORBOL 13 ACETATE 12 MYRISTATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOASSAY; CARCINOGEN TESTING; CARCINOGENICITY; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENOTOXICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXICITY TESTING; TRANSGENIC MOUSE;

ANABOLIC AGENTS; ANIMALS; CARCINOGENICITY TESTS; CARCINOGENS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; OXYMETHOLONE; PAPILLOMA; SEX FACTORS; SKIN NEOPLASMS; SURVIVAL RATE; WEIGHT GAIN;

ANIMALIA; MUS MUSCULUS; RODENTIA;

EID: 0032829722     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262339902700502     Document Type: Article

References (16)

1. Anonymous (1995). ANADROL©-50. In: Physician's Desk Reference, 49th ed. Medical Economics Data Production Co., Montvale, New Jersey, pp. 2458-2459.
2. Ashby J. and Tennant RW (1994). Prediction of rodent carcinogenicity for 44 chemicals: Results. Mutagenesis 9: 7-15.
3. Bootman J. (1996). Speculations on the rodent carcinogenicity of 30 chemicals currently under evaluation in rat and mouse bioassays organized by the U.S. National Toxicology Program. Environ. Mol. Mutagen. 27: 237-243.
4. Capecchi MR (1989). Altering the genotype by homologous recombination. Science 244: 1288-1292.
5. Holden HE, Stoll RE, Spalding JW, and Tennant RW (1998). Hemizygous Tg.AC transgenic mouse as a potential alternative to the two-year mouse carcinogenicity bioassay: Evaluation of husbandry and housing factors. J. Appl. Toxicol. 18: 19-24.
6. Holden HE, Studwell D., and Majeska JB (1999). Oxymetholone: I. Evaluation in a comprehensive battery of genetic toxicology and in vitro transformation assays. Toxicol. Pathol. 27: 501-506 (this issue).
7. Leder A., Kuo A., Cardiff R., Sinn E., and Leder P. (1990). v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: Effect of phorbol esters and retinoic acid. Proc. Natl. Acad. Sci. USA 87: 9178-9182.
8. Monro A. (1993). How useful are chronic (life-span) toxicology studies in rodents in identifying pharmaceuticals that pose a carcinogenic risk to humans? Adverse Drug React. Toxicol. Rev. 12: 5-34.
9. Monro A. (1996). Are lifespan rodent carcinogenicity studies defensible for pharmaceutical agents? Exp. Toxicol. Pathol. 48: 155-166.
10. Robinson D. (1998). The International Life Sciences Institute's role in the evaluation of alternate methodologies for the assessment of carcinogenic risk. Toxicol. Pathol. 26: 474-475.
11. Spalding JW, Momma J., Elwell MR, and Tennant RW (1993). Chemically induced skin carcinogenesis in a transgenic mouse line (Tg.AC) carrying a v-Ha-ras gene. Carcinogenesis 14: 1335-1341.
12. Stoll RE, Holden HE, Barthel CH, and Blanchard KT (1999). Oxymetholone: III. Evaluation in the p53+/- transgenic mouse model. Toxicol. Pathol. 27: 513-518 (this issue).
13. Studwell D., Holden HE, and Majeska JB (1997). Oxymetholone: A non-genotoxic carcinogen? Environ. Mol. Mutagen. 29: 49.
14. Tennant RW, French JE, and Spalding JW (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ. Health Perspect. 103: 942-950.
15. Tennant RW, Spalding JW, and French JE (1996). Evaluation of transgenic mouse bioassays for identifying carcinogens and non-carcinogens. Mutat. Res. 365: 119-127.
16. Zeiger E., Anderson B., Haworth S., Lawlor T., and Mortelmans K. (1992). Salmonella mutagenicity tests: V. Results from the testing of 311 chemicals. Environ. Mol. Mutagen. 19: 2-141.